Lilly Business Development at a Glance

Last Modified Date: February 21, 2018

Like many pharma giants, Eli Lilly and Company has a pipeline full of permutations of oncology assets. Their next biggest areas of focus are diabetes, neurodegeneration, and immunology. They have cash in the bank, and while pharma companies are striking deals left and right in the early weeks of 2018, Lilly has yet to announce any deals.

Lilly Stock

Eli Lilly and Company
Company Type: Large Pharma
Region: United States, Worldwide
Cash Position: USD 8 034M
Therapeutic Focus: Diabetes, Immunology, Neurodegeneration, Oncology, Pain


Deal Activity

Lilly Data

Figure 1. Eli Lilly and Company. In-Licensing Deals and Acquisitions, 2013 through Present (February 2018)

Recent Deal Highlights:

COLLABORATION WITH CUREVAC FOR mRNA CANCER VACCINES

Total Size: USD 1 795M | Upfront: USD 50M + EUR 45M | Therapeutic Area: Oncology | Date: October 2017

PRESS

COLLABORATION WITH TOPAS THERAPEUTICS FOR IMMUNE TOLERANCE INDUCING ASSETS

Disease Area: Immunology | Date: August 2017

PRESS

COLLABORATION WITH NEKTAR THERAPEUTICS FOR IL-2 TARGETING FIRST IN CLASS THERAPEUTIC

Total Size: USD 400M | Upfront: USD 150M | Disease Area: Immunology | Date: July 2017

PRESS

R&D PIPELINE

Lilly Pipeline

Figure 2. Eli Lilly and Company. R&D Pipeline at Present (February 2018)

Products from Recent Deals:

KEYBIOSCIENCE PARTNERED DUAL AMYLIN CALCITONIN RECEPTOR AGONISTS

Disease Area: Diabetes | Status: Type 2 Diabetes Phase II

ACQUIRED COLUCID ORAL 5-HT1F AGONIST LASMIDITAN

Disease Area: Pain | Status: Migraine Phase III | Cardiovascular Effects in the Elderly Phase I

ASTRAZENECA PARTNERED BACE INHIBITOR

Disease Area: Neurodegeneration | Status: Early Alzheimer's Disease Dementia Phase III

BUSINESS DEVELOPMENT TEAM

  • Director, Business Development | Timothy Dolan
  • Director, Business Development | Jullian Jones
  • Director, Business Development, Emerging Technology & Innovation | Kathryn McCabe
  • Director, BD, Neuroscience, Autoimmune, Endocrinology, Urology, Cardiovascular | David Kutoloski
  • Director, External Innovation, Global External R&D | Tim Luker
  • Senior Director, Business Development, Emerging Technology & Innovation | Stephen Curtis
  • Senior Vice President, Corporate Business Development | Darren Carroll
  • VP Business Development | Michael Johnson

Business profiles tailored to your asset.